Skip to main content
Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · ORMP ISIN · US68403P2039 LEI · 5299006K52ZIIGQJ6R84 TA Manufacturing
Open in API
Filings indexed 1,576 across all filing types
Latest filing 2026-01-15 M&A Activity
Country US United States of America
Listing TA ORMP

About Oramed Pharmaceuticals Inc.

https://www.oramed.com

Oramed Pharmaceuticals Inc. is a clinical-stage company focused on developing oral drug delivery systems for medications that are typically administered via injection. The company's core technology is its proprietary Protein Oral Delivery (POD™) platform, which is designed to protect therapeutic proteins from enzymatic degradation in the gastrointestinal tract and enhance their absorption into the bloodstream. Oramed's lead product candidate is an oral insulin capsule (ORMD-0801) for the treatment of diabetes. The company's pipeline also includes an oral GLP-1 analog capsule (ORMD-0901) for type 2 diabetes. Oramed aims to improve patient compliance, comfort, and therapeutic outcomes by converting injectable treatments into oral formulations.

Recent filings

Filing Released Lang Actions
FORM 8K-Lifeward will acquire all of the outstanding equity interests in Oratech from the Company; Lifeward will issue to the Company ordinary shares and pre-funded warrants equal to up to 49.99%
M&A Activity Classification · 100% confidence The document is a Form 8-K filed with the SEC by Oramed Pharmaceuticals Inc. It details the entry into a material definitive agreement, specifically a Share Purchase Agreement involving the acquisition of equity interests in a subsidiary (Oratech) by Lifeward Ltd. This type of corporate transaction, involving mergers, acquisitions, or significant divestitures, is classified under M&A Activity (TAR).
2026-01-15 English
FORM 8K-Lifeward will acquire all of the outstanding equity interests in Oratech from the Company; Lifeward will issue to the Company ordinary shares and pre-funded warrants equal to up to 49.99%
Report Publication Announcement Classification · 100% confidence The document is a short notification from Oramed Pharmaceuticals Inc. filed via the Israel Securities Authority (MAGNA system). It explicitly states 'Attached hereto is a report on Form 8-K' and provides a filename for the attachment. Following the 'Menu vs Meal' rule, since this is a short announcement stating that a report is attached rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2026-01-15 English
8-K Filing
Regulatory Filings
2026-01-14 English
Oramed will transfer POD™ platform to Lifeward, Oramed will receive 49.9% beneficial ownership interest in Lifeward
M&A Activity Classification · 100% confidence The document is a press release announcing a strategic transaction between Oramed Pharmaceuticals and Lifeward, involving the transfer of technology, equity ownership, and convertible note financing. This falls under the category of M&A activity and strategic corporate restructuring, which is classified as 'TAR' (M&A Activity).
2026-01-13 English
Oramed will transfer POD™ platform to Lifeward, Oramed will receive 49.9% beneficial ownership interest in Lifeward
Regulatory Filings Classification · 95% confidence The document is a short regulatory filing from Oramed Pharmaceuticals Inc. submitted via the Israel Securities Authority (MAGNA system). It explicitly states 'Attached hereto is a report on Press Release' and provides a filename (20260113_Oramed_PR_isa.pdf). Following the 'Menu vs Meal' rule, since this is a short announcement notifying the public of an attached report rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2026-01-13 English
Oramed Receives $18 Million Payment from Scilex Holdings; approved a cash dividend t of $0.25 per share, ex-dividend date of January 16, 2026 with disbursement scheduled for January 26, 2026
Notice of Dividend Amount Classification · 95% confidence The document is a Form 8-K filed with the SEC by Oramed Pharmaceuticals Inc. While it contains information about a dividend declaration, Form 8-K is a standard regulatory filing used to report material events. According to the classification rules, 'Regulatory Filings' (RNS) serves as the fallback category for miscellaneous filings that do not fit into other specific categories, and since this is a formal SEC 8-K filing covering multiple events (a payment receipt and a dividend announcement), it is best classified as a regulatory filing.
2026-01-07 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.